Cargando…
Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review
The development of acute lymphoblastic leukemia (ALL) from myelodysplastic syndrome (MDS) is a very rare event. The current report presents a rare case of a 33-year-old man who was diagnosed with MDS with multiple-lineage dysplasia (MDS-MLD) that transformed into pro-B-ALL. A missense mutation (S123...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958712/ https://www.ncbi.nlm.nih.gov/pubmed/29805685 http://dx.doi.org/10.3892/ol.2018.8546 |
_version_ | 1783324282209697792 |
---|---|
author | Guo, Zhi-Ping Tan, Yan-Hong Li, Jian-Lan Xu, Zhi-Fang Chen, Xiu-Hua Xu, Lian-Rong |
author_facet | Guo, Zhi-Ping Tan, Yan-Hong Li, Jian-Lan Xu, Zhi-Fang Chen, Xiu-Hua Xu, Lian-Rong |
author_sort | Guo, Zhi-Ping |
collection | PubMed |
description | The development of acute lymphoblastic leukemia (ALL) from myelodysplastic syndrome (MDS) is a very rare event. The current report presents a rare case of a 33-year-old man who was diagnosed with MDS with multiple-lineage dysplasia (MDS-MLD) that transformed into pro-B-ALL. A missense mutation (S1231F) of the additional sex combs like 1, transcriptional regulator gene was identified, which may have a substantial role in the progression, however does not act as an unfavorable prognostic marker. The patient died during induction chemotherapy. The present study further conducted an analysis on 30 patients to determine progression to ALL. Patients were predominantly male (76.7%, 23/30) with a median age of 56 years (3–90 years). The median time to transformation was 5.5 months (2–50 months). The most common type of MDS with ALL transformation comprised of MDS-excess blasts (MDS-EB; 40%, 12/30), MDS with single-lineage dysplasia (MDS-SLD; 30%, 9/30) and MDS with ring sideroblasts (MDS-RS; 16.7%, 5/30). The majority of the patients transformed to B-cell (66.7%, 16/24) followed by T-cell (33.3%, 8/24) ALL. From the 25 cases where data was available, the complete remission rate was 75% (15/20) with ALL-directed chemotherapy and the median remission duration was 15 months (range 4.5 to 51 months). However, the results indicated that ALL following MDS is characterized by a high rate of early death (20%, 5/25). |
format | Online Article Text |
id | pubmed-5958712 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-59587122018-05-27 Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review Guo, Zhi-Ping Tan, Yan-Hong Li, Jian-Lan Xu, Zhi-Fang Chen, Xiu-Hua Xu, Lian-Rong Oncol Lett Articles The development of acute lymphoblastic leukemia (ALL) from myelodysplastic syndrome (MDS) is a very rare event. The current report presents a rare case of a 33-year-old man who was diagnosed with MDS with multiple-lineage dysplasia (MDS-MLD) that transformed into pro-B-ALL. A missense mutation (S1231F) of the additional sex combs like 1, transcriptional regulator gene was identified, which may have a substantial role in the progression, however does not act as an unfavorable prognostic marker. The patient died during induction chemotherapy. The present study further conducted an analysis on 30 patients to determine progression to ALL. Patients were predominantly male (76.7%, 23/30) with a median age of 56 years (3–90 years). The median time to transformation was 5.5 months (2–50 months). The most common type of MDS with ALL transformation comprised of MDS-excess blasts (MDS-EB; 40%, 12/30), MDS with single-lineage dysplasia (MDS-SLD; 30%, 9/30) and MDS with ring sideroblasts (MDS-RS; 16.7%, 5/30). The majority of the patients transformed to B-cell (66.7%, 16/24) followed by T-cell (33.3%, 8/24) ALL. From the 25 cases where data was available, the complete remission rate was 75% (15/20) with ALL-directed chemotherapy and the median remission duration was 15 months (range 4.5 to 51 months). However, the results indicated that ALL following MDS is characterized by a high rate of early death (20%, 5/25). D.A. Spandidos 2018-06 2018-04-20 /pmc/articles/PMC5958712/ /pubmed/29805685 http://dx.doi.org/10.3892/ol.2018.8546 Text en Copyright: © Guo et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Guo, Zhi-Ping Tan, Yan-Hong Li, Jian-Lan Xu, Zhi-Fang Chen, Xiu-Hua Xu, Lian-Rong Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review |
title | Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review |
title_full | Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review |
title_fullStr | Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review |
title_full_unstemmed | Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review |
title_short | Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review |
title_sort | acute pro-b-cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an asxl1 missense mutation: a case report with literature review |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958712/ https://www.ncbi.nlm.nih.gov/pubmed/29805685 http://dx.doi.org/10.3892/ol.2018.8546 |
work_keys_str_mv | AT guozhiping acuteprobcelllymphoblasticleukemiatransformedfrommyelodysplasticsyndromewithanasxl1missensemutationacasereportwithliteraturereview AT tanyanhong acuteprobcelllymphoblasticleukemiatransformedfrommyelodysplasticsyndromewithanasxl1missensemutationacasereportwithliteraturereview AT lijianlan acuteprobcelllymphoblasticleukemiatransformedfrommyelodysplasticsyndromewithanasxl1missensemutationacasereportwithliteraturereview AT xuzhifang acuteprobcelllymphoblasticleukemiatransformedfrommyelodysplasticsyndromewithanasxl1missensemutationacasereportwithliteraturereview AT chenxiuhua acuteprobcelllymphoblasticleukemiatransformedfrommyelodysplasticsyndromewithanasxl1missensemutationacasereportwithliteraturereview AT xulianrong acuteprobcelllymphoblasticleukemiatransformedfrommyelodysplasticsyndromewithanasxl1missensemutationacasereportwithliteraturereview |